High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: Down-regulatory effects of statins

Cardiovascular Research

Volumn 79, Issue 1, 2008, Pages 195-203

  Smith, Camilla ^a   Halvorsen, Bente ^a   Otterdal, Kari ^a   Wæhre, Torgun ^a   Yndestad, Arne ^a   Fevang, Børre ^a   Sandberg, Wiggo J ^a   Breland, Unni M ^a   Frøland, Stig S ^a   Øie, Erik ^a   Gullestad, Lars ^a   Damås, Jan K ^a   Aukrust, Pål ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Atherosclerosis; Chemokines; Coronary artery disease; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CXCL16 CHEMOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; METALLOPROTEINASE; PROTEINASE; SIMVASTATIN; WARFARIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LIPID METABOLISM; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEINASE INHIBITION;

AGED; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES, CXC; CORONARY ARTERY DISEASE; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PYRROLES; RECEPTORS, SCAVENGER; SIMVASTATIN;

EID: 45849113196     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn071     Document Type: Article

References (37)

1. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897.
2. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998;101:353-363.
3. -/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003;11:333-340.
4. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P et al. Expression cloning of the strl33/bonzo/tymstr ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166:5145-5154.
5. Abel S, Hundhausen C, Mentlein R, Schulte AM, Berkhout TA, Broadway N et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-γ and TNF-α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004;172:6362-6372.
6. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita Tet al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000;275:40663- 40666.
7. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K, Akiyama Y et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001;21:1796-1800.
8. Wuttge DM, Zhou X, Sheikine Y, Wågsäter D, Stemme V, Hedin U et al. CXCL16/SR-PSOX is an interferon-γ-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750-755.
9. Sheikine Y, Bang CS, Nilsson L, Samnegård A, Hamsten A, Jonasson L et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis 2006;188:462-466.
10. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RC, Szapary P, Wilensky R et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007;49:442-449.
11. Aslanian A, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006;114:583-590.
12. Wæhre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors downregulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003;41:1460-1467.
13. Otterdal K, Smith C, Øie E, Pedersen TM, Yndestad A, Stang E et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 2006;108:928-935.
14. Yndestad A, Holm AM, Müller F, Simonsen S, Frøland SS, Gullestad L et al. Enhanced expression of inflammatory cytokines activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-146.
15. Halvorsen B, Staff AC, Ligaarden S, Prydz K, Kolset SO. Lithocholic acid and sulphated lithocholic acid differ in the ability to promote matrix metalloproteinase secretion in the human colon cancer cell line CaCo-2. Biochem J 2000;349:189-193.
16. Wæhre T, Yndestad A, Smith C, Haug T, Haugen Tunheim SH, Gullestad L et al. Increased expression of interleukin 1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004;109:1966-1972.
17. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109(Suppl. 2):II18-II26.
18. + T cells in cardiac valves during inflammatory valvular heart disease. Arterioscler Thromb Vasc Biol 2004;24:282-287.
19. Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007;178:8064-8072.
20. Wagsater D, Olofsson P, Norgren L, Stenberg B, Sirsjo A. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon-gamma. Biochem Biophys Res Commun 2004;325:1187-1193.
21. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26.
22. Agostini C, Cabrelle A, Calabrese F, Bortoli M, Scquizzato E, Carraro S et al. Role for CXCR6 and its ligand CXCL16 in the pathogenesis of T-cell alveolitis in sarcoidosis. Am J Respir Crit Care Med 2005;172:1290-1298.
23. Ludwig A, Weber C. Transmembrane chemokines: Versatile 'special agents' in vascular inflammation. Thromb Haemost 2007;97:694-703.
24. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 2008;28:245-251.
25. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK III et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006;54:765-778.
26. le Blanc LMP, van Lieshout AWT, Adema GJ, van Riel PLCM, Verbeek MM, Radstake TRDJ. CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. Neurosci Lett 2006;397:145-148.
27. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004;279:3188-3196.
28. Geissmann F, Cameron TO, Sidobre S, Manlongat N, Kronenberg M, Briskin MJ et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005;3:e113.
29. Hase K, Murakami T, Takatsu H, Shimaoka T, Iimura M, Hamura K et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006;176:43-51.
30. Garcia GE, Truong LD, Li P, Zhang P, Johnson RJ, Wilson CB et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of antiglomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007;170:1485-1496.
31. Galkina E, Harry BL, Ludwig A, Liehn EA, Sanders JM, Bruce A et al. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-γ production, and macrophage accumulation in the aortic wall. Circulation 2008;116:1801-1811.
32. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004;172:3678-3685.
33. Landsberger M, Wolff B, Jantzen F, Rosenstengel C, Vogelgesang D, Staudt A et al. Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells. Atherosclerosis 2007;190:43-52.
34. Takeuchi S, Kawashima S, Rikitake Y, Ueyama T, Inoue N, Hirata K et al. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem Biophys Res Commun 2000;269:97-102.
35. Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002;34:451-461.
36. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNFα-induced adhesion molecules expression in human endothelial cells. Life Sci 2004;75:1287-1302.
37. Breland UM, Halvorsen B, Hol J, Øie E, Paulsson-Berne G, Yndestad A et al. A potential role of the CXC chemokine GROα in atherosclerosis and plaque destabilization. Down-regulatory effects of statins. Arterioscler Thromb Vasc Biol 2008; Epub ahead of print.